FDA would be required to develop and implement a five-year “action plan” to foster development of new treatments for ALS and other rare neurological disorder under a bill that appears primed to move quickly through the House of Representatives.
ACT for ALS directs FDA to publish a five-year action plan within six months of the date of enactment,...







